Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

However, in contrast, the ITT analysis estimated a 37% reduction in persistent diarrhea or death by day 12 (95% CI, 2%–60%; P = .037), whereas mITT/per-protocol analyses of clinical failure/cure (also assessed at day 12) suggested smaller benefits associated with fidaxomicin that did not reach statistical significance ( P = .40 and P = .33, respectively).

also in 111,027 other papers